St Jude Medical Begins VecToR
Selected Abstract
St. Jude Medical Begins VecToR Trial to Evaluate Low-Voltage Biventricular Resynchronization Stimulation Therapy in Heart Failure (HF) Patients.
ST. PAUL, Minn., Oct. 12 /PRNewswire/ -- St. Jude Medical (NYSE: STJ) today announced that it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its Ventricular Resynchronization Therapy Randomized (VecToR) clinical trial. Using the ... October 12, 2000; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
St. Jude Medical Begins VecToR Trial to Evaluate Low-Voltage Biventricular Resynchronization Stimulation Therapy in Heart Failure (HF) Patients.
|
